The natural disease course of chronic obstructive pulmonary disease (COPD) is often
punctuated by exacerbations: acute events of symptom worsening associated with …

Bronchodilators are the cornerstone of symptomatic chronic obstructive pulmonary disease
(COPD) treatment. They are routinely recommended for symptom reduction, with a …

Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines1 recommend
either a long-acting beta-agonist (LABA) plus an inhaled glucocorticoid or a long-acting …

Decreasing the frequency and severity of exacerbations is one of the main goals of
treatment for patients with chronic obstructive pulmonary disease. Several studies have …

Exacerbations of chronic obstructive pulmonary disease (COPD) are natural events in the
progression of the disease, and are characterised by acute worsening of symptoms …

Exacerbations, which often lead to emergency department visits and hospitalizations, are
the main drivers of morbidity and utilization of health care resources among patients with …

Background: Most patients with moderate and severe chronic obstructive pulmonary disease
(COPD) receive long-acting bronchodilators (LABA) for symptom control. It is, however …

Objectives This study aimed to quantitatively compare the efficacy and safety of long-acting
β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) and LABA/inhaled …

Because there is a solid pharmacological rationale based on positive interactions between
long‐acting muscarinic receptor antagonists (LAMAs) and long‐acting β‐agonists (LABAs) …

Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity
and mortality globally. In the major revision of the Global Initiative for Chronic Obstructive …